Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 to 60 years inclusive, at the time of the first vaccination.~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.~* Written informed consent obtained from the subject.~* Satisfactory baseline medical assessment by history and physical examination.~* Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line or mobile, but NOT a pay phone or multiple-user device~* Females of non-childbearing potential may be enrolled in the study.~* Female of childbearing potential may be enrolled in the study, if she:~* has practiced adequate contraception for 30 days prior to vaccination, and~* has a negative pregnancy test on the day of vaccination, and~* has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period.~* Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.~* Presence of an axillary temperature \>= 37.5°C (99.5°F), or acute symptoms greater than mild severity on the scheduled date of first vaccination. NOTE: The subject may be vaccinated at a later date, provided symptoms have resolved, vaccination occurs within the window specified by the protocol, and all other eligibility criteria continue to be satisfied.~* Clinically or virologically confirmed influenza infection within 6 months preceding the study start.~* Diagnosed with cancer, or treatment for cancer, within 3 years.~* Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.~* Clinically or virologically confirmed influenza infection within 6 months preceding the study start.~* Chronic administration of immunosuppressants or other immune modifying drugs within 6 months of study enrolment or planned administration during the study period.~* Receipt of any immunoglobulins and/or any blood products within 3 months of study enrolment or planned administration of any of these products during the study period.~* Any significant disorder of coagulation or treatment with warfarin derivatives or heparin.~* An acute evolving neurological disorder or history of Guillain-Barré syndrome.~* Administration of any vaccines within 30 days before vaccination.~* Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.~* Pregnant or lactating female~* Female planning to become pregnant or planning to discontinue contraceptive precautions.~* Any conditions which, in the opinion of the investigator, prevents the subjects from participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- GSK2340272A GROUP (Type: EXPERIMENTAL): Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
- GSK2340274A GROUP (Type: EXPERIMENTAL): Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340274A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.

Based on this trial design, predict the completion outcome and termination type (if applicable).